Home-based follow-up for colorectal cancer patients after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the quality of life and reduce stress for colorectal cancer patients by implementing a patient-led follow-up program from home. Patients will perform blood tests for CEA determination, complete quality of life questionnaires, and monitor vital parameters using a smart sensor. The program seeks to provide a personalized surveillance experience that is non-inferior to traditional in-hospital follow-up care over a 36-month period. By relocating follow-up care to the home setting, the study also aims to decrease the number of in-hospital appointments required for these patients.

Why it matters

Who can join: the full rules

inclusion criteria

* Age ≥ 21 years
* Histologically confirmed colorectal adenocarcinoma without distant metastasis and treated with curative intent surgical resection less than 6 months ago
* Scheduled or currently undergoing postoperative surveillance according to national guidelines
* Written informed consent by the patient
* Access to a smartphone

Exclusion criteria

* Patients with a severely complicated postoperative course, needing in hospital follow- up longer than 6 months postoperatively
* Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging - yearly or more frequent - of the abdomen and/or thorax
* Patients with comorbidity or other malignancy that requires imaging of the abdomen and/or thorax every year or more frequent
* Patients with active implantable devices - e.g. pacemaker or implantable defibrillator
* Inability to complete the questionnaires due to illiteracy and/or insufficient proficiency of the Dutch language

Where it's running

• Erasmus Medical Center
  Rotterdam, South Holland, Netherlands Recruiting
• Franciscus Gasthuis and Vlietland
  Rotterdam, South Holland, Netherlands Recruiting
• Amphia Hospital
  Breda, North Brabant, Netherlands Not yet recruiting
• IJsselland Hospital
  Capelle aan den IJssel, South Holland, Netherlands Not yet recruiting
• Leiden University Medical Center
  Leiden, South Holland, Netherlands Not yet recruiting

Study contacts

• Principal investigator: Dirk J. Grunhagen, MD, PhD — Erasmus Medical Center
• Study coordinator: Elise M.H.E. van Driel, MD
• Email: m.h.e.vandriel@erasmusmc.nl
• Phone: +310107042125

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• THE-0504 in patients with solid tumors

  A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.

  Recruiting Phase 1 Thena Biotech S.r.l. · Rome, Lazio · NCT07646106

• Effect of pre-surgery (neoadjuvant) therapy on surgical outcomes in colorectal cancer

  We will test whether pre-surgery (neoadjuvant) therapy changes tiny blood vessels, increases tissue scarring, and raises the risk of wound and other perioperative complications in adults having colorectal cancer surgery.

  Recruiting Osijek University Hospital · Osijek · NCT07422974

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Pirfenidone plus PD-1 inhibitor with or without targeted radiotherapy for advanced colorectal cancer

  This study tests whether combining pirfenidone with a PD-1 inhibitor, with or without hypofractionated radiotherapy, is safe and helps people with unresectable or metastatic pMMR/MSS colorectal cancer who have exhausted standard therapies.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07644286

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.